Invectys SA, of Paris, received €15 million (US$17 million) in a series A financing led by an undisclosed life sciences-savvy family office. The company plans to use the capital to fund a phase II trial testing INVAC-1 in patients with chronic lymphocytic leukemia. Invectys has raised €38 million since being founded in 2010.